抗骨粗鬆症療法と骨折治癒市場- 世界の産業規模、シェア、動向、機会、予測、薬剤タイプ別、投与経路別、流通チャネル別、地域別セグメント、競合、2020年～2030年

世界の抗骨粗鬆症療法と骨折治癒市場は、2024年に151億5,000万米ドルと評価され、2030年までのCAGRは4.43%で、予測期間には196億5,000万米ドルに達すると予測されています。

骨粗鬆症は、骨の弱体化を特徴とする広範な骨格障害であり、骨折のリスクを高め、その後、骨折治癒合併症を引き起こします。この疾患は、特に世界人口の高齢化が進む中、世界の健康上の大きな課題となっています。世界の抗骨粗鬆症療法と骨折治癒市場は、ヘルスケア専門家、製薬会社、医学研究者がこの衰弱状態に立ち向かおうとしているため、目覚ましい成長と技術革新を目の当たりにしています。骨粗鬆症は、骨折が起こるまで自覚症状がないまま進行するため、しばしば「沈黙の病」と呼ばれます。骨粗鬆症になると、骨は密度と強度を失い、多孔質でもろくなります。その結果、特に股関節、脊椎、手首で骨折しやすくなります。骨粗鬆症は主に閉経後の女性が罹患するが、男性やあらゆる年齢の人にも影響を及ぼす可能性があります。

同市場では、薬物療法、医療機器、外科的処置、生活習慣の改善など、多様な治療オプションが提供されています。これらの選択肢は、骨粗鬆症の治療だけでなく、骨折後の治癒プロセスを高めることも目的としています。低侵襲手術技術や再生療法などの最先端技術は、骨粗鬆症治療と骨折治癒の効果を高めています。

主な市場促進要因

高齢化人口の増加が世界の抗骨粗鬆症療法と骨折治癒市場を牽引

主な市場課題

人口の高齢化

主要市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の抗骨粗鬆症療法と骨折治癒市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤タイプ別（カルシトニン、ビスフォスフォネート、ホルモン補充療法、アナボリック、その他）
  • 投与経路別（経口、注射）
  • 流通チャネル別（病院薬局、小売薬局、eコマース）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 薬の種類別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋地域の抗骨粗鬆症療法と骨折治癒市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬の種類別
  • 投与経路別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の抗骨粗鬆症療法と骨折治癒市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の抗骨粗鬆症療法と骨折治癒市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の抗骨粗鬆症療法と骨折治癒市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの抗骨粗鬆症療法と骨折治癒市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の抗骨粗鬆症療法と骨折治癒市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• GlaxoSmithKline plc
• Medtronic Plc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer inc.
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.
• Orthofix US LLC

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Anti Osteoporosis Therapy and Fracture Healing Market was valued at USD 15.15 Billion in 2024 and is and is expected to reach USD 19.65 Billion in the forecast period with a CAGR of 4.43% through 2030. Osteoporosis is a pervasive skeletal disorder characterized by weakened bones, increasing the risk of fractures and, subsequently, fracture healing complications. This condition poses a significant global health challenge, especially as the world's population continues to age. The global anti-osteoporosis therapy and fracture healing market has been witnessing remarkable growth and innovation as healthcare professionals, pharmaceutical companies, and medical researchers seek to combat this debilitating condition. Osteoporosis is often referred to as the 'silent disease' because it progresses without symptoms until a fracture occurs. In osteoporotic individuals, bones lose their density and strength, becoming more porous and fragile. This results in a higher susceptibility to fractures, particularly in the hip, spine, and wrist. Osteoporosis predominantly affects postmenopausal women, but it can also impact men and individuals of all ages.

The market offers a diverse range of treatment options, including medications, medical devices, surgical procedures, and lifestyle modifications. These options aim to not only treat osteoporosis but also enhance the healing process after a fracture. Cutting-edge technologies, such as minimally invasive surgical techniques and regenerative therapies, are enhancing the effectiveness of osteoporosis treatment and fracture healing.

Key Market Drivers

Rising Aging Population is Driving the Global Anti Osteoporosis Therapy and Fracture Healing Market

The global healthcare landscape is undergoing a significant transformation, largely driven by the aging population. As people live longer, they are more likely to experience age-related health issues, one of the most common being osteoporosis. This bone disease, characterized by decreased bone density and increased fragility, poses a considerable threat to the elderly, resulting in fractures that can have debilitating consequences. The rising aging demographic has given rise to a thriving market for anti-osteoporosis therapy and fracture healing solutions.

The world's population is aging at an unprecedented rate. Advancements in healthcare, nutrition, and lifestyle choices have led to increased life expectancy. This demographic shift is observed across developed and developing countries alike, albeit at varying rates. According to the United Nations, by 2050, the global population aged 60 and above will surpass 2 billion, accounting for more than 20% of the total population. As individuals age, their bone density naturally decreases. This gradual weakening of the bones is a significant factor behind the increased prevalence of osteoporosis. Osteoporosis is often referred to as a "silent disease" because it progresses without obvious symptoms until a fracture occurs. Fractures, especially hip fractures, can have devastating consequences for the elderly, leading to reduced mobility, chronic pain, and increased mortality rates.

Growing awareness about osteoporosis and its implications on bone health has encouraged individuals to seek early diagnosis and treatment. This has driven the demand for anti-osteoporosis therapies. The development of innovative diagnostic tools and therapeutic options for osteoporosis has improved the treatment landscape. This includes medications to strengthen bones and reduce fracture risk, as well as cutting-edge surgical techniques for fracture healing. Public and private research organizations, along with pharmaceutical companies, are investing heavily in osteoporosis research. This collaboration has led to a better understanding of the disease and the development of more effective treatments.

Key Market Challenges

Aging Population

One of the most significant challenges facing the market is the global aging population. As people live longer, the prevalence of osteoporosis and fractures increases. The demand for effective therapies and fracture healing solutions is surging, leading to a strain on healthcare systems and resources. This challenge necessitates the development of cost-effective and scalable treatments to meet the growing demand.

Key Market Trends

Technological Advancements

Technological advancements have revolutionized the diagnosis of osteoporosis. Traditional methods, such as X-rays, while still valuable, have limitations. Dual-energy X-ray absorptiometry (DXA) scans are now widely used for bone density measurements, enabling early detection of osteoporosis. Furthermore, portable and cost-effective devices that use ultrasound to measure bone density are becoming increasingly accessible, allowing for early screening in primary care settings. Imaging technologies like magnetic resonance imaging (MRI) and computed tomography (CT) scans have evolved to provide better visualization of bone structure, helping doctors detect fractures and monitor healing. Three-dimensional printing and modeling have also made significant strides, allowing for the creation of personalized implants and prosthetics for patients with complex fractures. Pharmaceutical companies are investing in innovative drug development to combat osteoporosis. Targeted therapies, such as monoclonal antibodies and selective estrogen receptor modulators, are becoming available, offering a more specific and effective approach to treatment. Additionally, genetic testing and personalized medicine are contributing to the development of tailored treatment plans based on individual patients' genetics, lifestyle, and risk factors.

Telemedicine and digital health solutions are playing a crucial role in osteoporosis management. Patients can now access consultations with specialists remotely, ensuring timely and efficient care. Wearable devices and mobile apps provide tools for monitoring bone health, encouraging adherence to therapy regimens, and enabling real-time data transmission to healthcare providers for a more comprehensive approach to care. In the field of fracture healing, surgical techniques have advanced significantly. Minimally invasive procedures, such as arthroscopy, have reduced recovery times and complications associated with surgery. In orthopedics, advancements in implant materials and design have improved the success rates of joint replacements, enhancing the quality of life for patients.

The development of regenerative medicine approaches for fracture healing is a promising avenue. Stem cell therapies, tissue engineering, and growth factors are being explored to accelerate the body's natural healing processes. These techniques aim to not only repair the bone but also restore its functionality, reducing the risk of long-term complications. Artificial intelligence (AI) and data analytics are enhancing disease prediction, diagnosis, and treatment outcomes in osteoporosis. Machine learning algorithms can analyze large datasets to identify high-risk individuals and predict fractures, enabling early intervention. AI is also used to optimize drug discovery processes, potentially leading to more effective treatments.

Key Market Players

• GlaxoSmithKline plc
• Medtronic Plc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer inc.
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.
• Orthofix US LLC

Report Scope:

In this report, the Global Anti Osteoporosis Therapy and Fracture Healing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti Osteoporosis Therapy and Fracture Healing Market, By Drug Type:

• Calcitonin
• Bisphosphonates
• Hormone Replacement Therapy
• Anabolic
• Others

Anti Osteoporosis Therapy and Fracture Healing Market, By Route of Administration:

• Oral
• Injectable

Anti Osteoporosis Therapy and Fracture Healing Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

Anti Osteoporosis Therapy and Fracture Healing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Anti Osteoporosis Therapy and Fracture Healing Market.

Available Customizations:

Global Anti Osteoporosis Therapy and Fracture Healing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Anti Osteoporosis Therapy and Fracture Healing Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Drug Type (Calcitonin, Bisphosphonates, Hormone Replacement Therapy, Anabolic, Others)
  • 4.2.2. By Route of Administration (Oral, Injectable)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Drug Type
  • 4.3.2. By Route of Administration
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Anti Osteoporosis Therapy and Fracture Healing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type
  • 5.2.2. By Route of Administration
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Drug Type
      • 5.3.1.2.2. By Route of Administration
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Drug Type
      • 5.3.2.2.2. By Route of Administration
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Drug Type
      • 5.3.3.2.2. By Route of Administration
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Drug Type
      • 5.3.4.2.2. By Route of Administration
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Drug Type
      • 5.3.5.2.2. By Route of Administration
      • 5.3.5.2.3. By Distribution Channel

6. Europe Anti Osteoporosis Therapy and Fracture Healing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Type
      • 6.3.4.2.2. By Route of Administration
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Type
      • 6.3.5.2.2. By Route of Administration
      • 6.3.5.2.3. By Distribution Channel

7. North America Anti Osteoporosis Therapy and Fracture Healing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel

8. South America Anti Osteoporosis Therapy and Fracture Healing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Anti Osteoporosis Therapy and Fracture Healing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Anti Osteoporosis Therapy and Fracture Healing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Anti Osteoporosis Therapy and Fracture Healing Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. GlaxoSmithKline plc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Product & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Medtronic Plc.
• 14.3. Merck & Co. Inc.
• 14.4. Novartis AG
• 14.5. Pfizer inc.
• 14.6. Eli Lilly and Co.
• 14.7. F. Hoffmann-La Roche Ltd
• 14.8. Stryker Corporation
• 14.9. Teva Pharmaceutical Industries Ltd.
• 14.10.Orthofix US LLC

15. Strategic Recommendations

16. About Us & Disclaimer